PMID- 29382418
OWN - NLM
STAT- MEDLINE
DCOM- 20180809
LR  - 20180809
IS  - 1007-8738 (Print)
IS  - 1007-8738 (Linking)
VI  - 33
IP  - 12
DP  - 2017 Dec
TI  - [Knockdown of indoleamine 2, 3-dioxygenase 2 (IDO2)gene inhibits tumor growth and 
      enhances immune function in mice bearing melanoma].
PG  - 1605-1609
AB  - Objective To study the role of indoleamine 2, 3-dioxygenase 2 (IDO2) in 
      anti-tumor therapy and its effect on the immune response when using IDO2 as 
      therapeutic target. Methods B16-BL6 cells were used to construct mouse 
      xenografted melanoma model. IDO2-shRNA that contained IDO2-siRNA or control shRNA 
      (scrambled-shRNA) was injected hydrodynamically via the tail vein to treat 
      melanoma. The tumor size was measured by vernier caliper. Flow cytometry was 
      performed to analyze the percentage of regulatory T cells (Tregs), T cell 
      apoptosis rate in draining lymph nodes and the expressions of co-stimulatory 
      molecules on splenic dendritic cells (DCs) from different treatment groups. The 
      lactate dehydrogenase (LDH) assay was used to determine the CD8(+) cytotoxic T 
      lymphocyte (CTL) activity. The serum levels of tumor necrosis factor alpha (TNF-alpha) 
      and interferon gamma (IFN-gamma) were detected by ELISA. Results In the IDO2-shRNA 
      treated group, the tumor formation time was delayed, tumor grew slowly, and 
      excised tumor mass was significantly reduced. IDO2-shRNA treatment also decreased 
      the percentage of Tregs and T cell apoptosis in draining lymph nodes and 
      increased the expressions of co-stimulatory molecules CD80 and CD86 on splenic 
      DCs. The capacity of CD8(+) T cells to kill B16-BL6 cells was enhanced and the 
      serum levels of TNF-alpha and IFN-gamma were upregulated. Conclusion Silencing IDO2 can 
      effectively inhibit the growth of melanoma and improve the anti-tumor immune 
      response in vivo.
FAU - Liu, Yanling
AU  - Liu Y
AD  - Jiangxi University of Technology, Nanchang 330098, China.
FAU - Liu, Huan
AU  - Liu H
AD  - Jiangxi University of Technology, Nanchang 330098, China.
FAU - Xiang, Yingqing
AU  - Xiang Y
AD  - Jiangxi University of Technology, Nanchang 330098, China.
FAU - Chen, Xiaoyan
AU  - Chen X
AD  - Jiangxi University of Technology, Nanchang 330098, China.
FAU - Xu, Ping
AU  - Xu P
AD  - Jiangxi University of Technology, Nanchang 330098, China.
FAU - Min, Weiping
AU  - Min W
AD  - Jiangxi Academy of Medical Sciences, Nanchang 330006; Institute of Immunology and 
      Biological Therapy, Nanchang University, Nanchang 330006, China. *Corresponding 
      author, E-mail: weiping.min@uwo.ca.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
JT  - Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular 
      immunology
JID - 101139110
RN  - 0 (IDO2 protein, mouse)
RN  - 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Dendritic Cells/immunology
MH  - Indoleamine-Pyrrole 2,3,-Dioxygenase/antagonists & 
      inhibitors/genetics/*physiology
MH  - Male
MH  - Melanoma, Experimental/drug therapy/immunology/*pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - RNA, Small Interfering/genetics
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Tumor Necrosis Factor-alpha/blood
EDAT- 2018/02/01 06:00
MHDA- 2018/08/10 06:00
CRDT- 2018/02/01 06:00
PHST- 2018/02/01 06:00 [entrez]
PHST- 2018/02/01 06:00 [pubmed]
PHST- 2018/08/10 06:00 [medline]
PST - ppublish
SO  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017 Dec;33(12):1605-1609.